Specialists believe that the drug, Remicade, is a major breakthrough in real proof that this drug is a major advance and my patients who have had it really have had their lives changed.

Remicade is J&J's biggest selling drug, with Q3 data showing sales of almost $1.8 billion, up more than 10% on the same period last year. Most of the sales are based in the US as the drug is ...

South Korea’s Celltrion Healthcare has begun a UK trial of its infliximab biosimilar to see if the drug can accelerate recovery from symptoms of COVID-19. The company noted that COVID-19 is ...

Please purchase a Premium Subscription to continue reading. To continue, please log in, or sign up for a new account. We offer one free story view per month. If you ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

South Korea’s Ministry of Food and Drug Safety approved 18 biosimilar products in 2024, making it a record year for domestic biosimilar approvals since the agency’s first nod of Celltrion Inc.’s ...

Jonathan Rockoff is the Health Business editor at The Wall Street Journal, managing a team that reports on pharmaceutical and biotechnology companies, health insurers and hospitals. During the ...